Effect of intraperitoneal hyperthermic perfusion chemotherapy at different times after operation on tumor marker levels in patients with ovarian cancer
Objective:To observe the effect of intraperitoneal hyperthermic perfusion chemotherapy at different times after operation on the levels of tumor markers in patients with ovarian cancer.Methods:A total of 84 ovarian cancer patients admitted to Liuzhou Workers hospital from June 2018 to December 2020 were selected as the study subjects, and they were randomly divided into either an observation group or a control group, with 42 cases in each group. Both groups of patients received intraperitoneal hyperthermic perfusion chemotherapy after radical resection of ovarian cancer. Patients in the observation group started their first intraperitoneal hyperthermic perfusion chemotherapy at 24 h after surgery, and repeated perfusion was performed every 24 h. Patients in the control group started the first intraperitoneal hyperthermic perfusion chemotherapy at 48 hours after the operation, and repeated infusion was performed every 48 hours. Both groups received a cycle of treatment consisting of 4 sessions of chemotherapy. Therapeutic effects and adverse reactions during chemotherapy were compared between the two groups. The levels of tumor markers and T lymphocytes in the two groups before and after treatment were also compared. After treatment, both groups of patients underwent a 1-year follow-up observation to calculate the survival rates of the two groups.Results:The objective remission rate and disease control rate of the observation group were 90.48% and 95.24%, respectively, which were significantly higher than those of the control group (71.43% and 80.95%, respectively, P＜0.05). The levels of VEGF, HE-4, and CA125 after treatment were significantly lower than those before treatment in both groups (P＜0.05), and the levels of VEGF, HE-4 and CA125 in the observation group were significantly lower than those in the control group after treatment (P＜0.05). The levels of CD3+ T cells, CD4+ T cells, and CD4+/CD8+ ratio after treatmen were significantly higher than those before treatment in both groups, and the level of CD8+ T cells was significantly lower than that before treatment (P＜0.05). There was no significant difference in the level of CD3+ T cells, CD4+ T cells, CD8+ T cells, or CD4+/CD8+ rate between the two groups after treatment (P＞0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups during treatment (P＞0.05). The 1-year survival rates of the observation group and the control group were 92.68% and 90.00%, respectively. Kaplan-Meier survival analysis showed that there was no significant difference in 1-year survival rates between the two groups (Log rank=0.191, P=0.662).Conclusion:The levels of tumor markers in patients with ovarian cancer receiving intraperitoneal hyperthermic perfusion chemotherapy every 24 hours after the operation decline more obviously.
万方数据
